Influenza A virus vaccine H1N1 - Omninvest

Drug Profile

Influenza A virus vaccine H1N1 - Omninvest

Alternative Names: FLUVAL P H1N1; Influenza virus vaccine H1N1 monovalent - Omninvest

Latest Information Update: 07 Feb 2014

Price : $50

At a glance

  • Originator Omninvest
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 01 Jan 2010 Launched for Influenza-A virus H1N1 subtype (prevention in children, adolescents and elderly) in Hungary (IM)
  • 06 Oct 2009 Registered for Influenza-A virus H1N1 subtype (prevention in children and adolescents aged 3-18 years) in Hungary (IM)
  • 06 Oct 2009 Registered for Influenza-A virus H1N1 subtype (in children aged 1-3 years) in Hungary (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top